Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Pancreatic Cancer
Both
Pancreatic Cancer
Trial Information
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
Inclusion Criteria:
- Patients with a mass in the pancreas suspicious for adenocarcinoma without biopsy
proven distant metastases.
- Patients who are scheduled for clinically indicated EUS
Exclusion Criteria:
- Patients who are medically unfit for endoscopic sedation or surgery due to severe
comorbid disease such as uncontrolled coronary disease, or oxygen dependant pulmonary
disease.
- Patients who have any other malignancy other than basal cell carcinoma within the
past 5 years.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.
Outcome Time Frame:
End of study
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
07-006640
NCT ID:
NCT00826982
Start Date:
January 2008
Completion Date:
Related Keywords:
- Pancreatic Cancer
- Pancreatic Neoplasms
Name | Location |
|---|---|
| Mayo Clinic | Jacksonville, Florida 32224 |
